Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access